In an exclusive interview with SFC, Dr. Pavol Dobrocky, the President and CEO of Boehringer Ingelheim Greater China, offers his perspective on the significant transformations and opportunities resulting from China's policies of reform and opening-up.
Dr. Pavol Dobrocky stated, Boehringer Ingelheim entered the Chinese market in 1994, and witnessed the tremendous changes China has gone through in the past three to four decades. These transformations encompass the robust growth of the Chinese economy and the immense opportunity to deliver innovative pharmaceuticals to a vast population of patients in China.
Related News
